Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
MP McGinley, JA Cohen - The Lancet, 2021 - thelancet.com
Summary The sphingosine 1-phosphate (S1P) signalling pathways have important and
diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for …
diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for …
Advancing the understanding of autism disease mechanisms through genetics
Progress in understanding the genetic etiology of autism spectrum disorders (ASD) has
fueled remarkable advances in our understanding of its potential neurobiological …
fueled remarkable advances in our understanding of its potential neurobiological …
Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies
AJ Sandweiss, VL Brandt, HY Zoghbi - The Lancet Neurology, 2020 - thelancet.com
The X-linked gene encoding MECP2 is involved in two severe and complex
neurodevelopmental disorders. Loss of function of the MeCP2 protein underlies Rett …
neurodevelopmental disorders. Loss of function of the MeCP2 protein underlies Rett …
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
B Lu, G Nagappan, X Guan, PJ Nathan… - Nature Reviews …, 2013 - nature.com
Increasing evidence suggests that synaptic dysfunction is a key pathophysiological hallmark
in neurodegenerative disorders, including Alzheimer's disease. Understanding the role of …
in neurodegenerative disorders, including Alzheimer's disease. Understanding the role of …
An update on the biology of sphingosine 1-phosphate receptors
Sphingosine 1-phosphate (S1P) is a membrane-derived lysophospholipid that acts primarily
as an extracellular signaling molecule. Signals initiated by S1P are transduced by five G …
as an extracellular signaling molecule. Signals initiated by S1P are transduced by five G …
Effects of aerobic exercise training on systemic biomarkers and cognition in late middle-aged adults at risk for Alzheimer's disease
Increasing evidence indicates that physical activity and exercise training may delay or
prevent the onset of Alzheimer's disease (AD). However, systemic biomarkers that can …
prevent the onset of Alzheimer's disease (AD). However, systemic biomarkers that can …
Neuronal plasticity and neurotrophic factors in drug responses
Neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) and other
members of the neurotrophin family, are central mediators of the activity-dependent plasticity …
members of the neurotrophin family, are central mediators of the activity-dependent plasticity …
Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial
Z Zhu, Y Fu, D Tian, N Sun, W Han, G Chang, Y Dong… - Circulation, 2015 - Am Heart Assoc
Background—Inflammatory and immune responses triggered by brain ischemia worsen
clinical outcomes of stroke and contribute to hemorrhagic transformation, massive edema …
clinical outcomes of stroke and contribute to hemorrhagic transformation, massive edema …
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
A Huwiler, U Zangemeister-Wittke - Pharmacology & therapeutics, 2018 - Elsevier
The immunomodulatory drug fingolimod (FTY720, Gilenya R) was approved for oral
treatment of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good …
treatment of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good …
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy
Fingolimod is the first oral disease-modifying therapy approved for relapsing forms of
multiple sclerosis (MS). Following phosphorylation in vivo, the active agent, fingolimod …
multiple sclerosis (MS). Following phosphorylation in vivo, the active agent, fingolimod …